Pretreatment of animals with fimasartan, an angiotensin II receptorinhibitor used clinically to treat hypertension and heart failure, reducedactivation of NLRP3, and protected animals from edema and neurological deficit.28 Glibenclamide, commonly used for treatment of type 2 diabetes mellitus,has been shown to protect the BBB after ICH in rats33 and mice86 by inhibiting the NLRP3 inflammasome and IL-1β release. This evidence concerns the gene NLRP3 and diabetes mellitus.